Overview

This trial is active, not recruiting.

Condition colorectal neoplasms
Treatments bevacizumab, 5-fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Phase phase 2
Target VEGF
Sponsor EPS Corporation
Start date May 2014
End date February 2017
Trial size 65 participants
Trial identifier NCT02246049, QUATTRO

Summary

The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Induction therapy is followed by the maintenance therapy. [Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. [Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
bevacizumab BV
Given IV
5-fluorouracil 5-FU
Given IV
irinotecan hydrochloride CPT-11
Given IV
leucovorin calcium I-LV
Given IV
oxaliplatin L-OHP
Given IV

Primary Outcomes

Measure
Progression-free survival (PFS) at 10 months
time frame: PFS rate at 10 months from study entry

Secondary Outcomes

Measure
Response rate (RR) by central review.
time frame: Up to 18 months
Response rate (RR) by investigator-reported measurements.
time frame: Up to 30 months
PFS by central review according to CT image.
time frame: Up to 18 months
Overall survival (OS)
time frame: Up to 30 months
Efficacy by RAS status ; RR,PFS,OS
time frame: Up to 30 months
Incidence of adverse events
time frame: Up to 30 months
Time to treatment-failure
time frame: Up to 30 months
Completion rate in Induction treatment
time frame: Up to 30 months
Relative Dose Intensity
time frame: Up to 30 months
Treatment duration
time frame: Up to 30 months

Eligibility Criteria

Male or female participants from 20 years up to 75 years old.

Inclusion Criteria: 1. Written Informed consent. 2. Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer. 3. Not resectable metastatic colorectal cancer 4. Age at enrollment is >= 20 and <= 75 years 5. ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years 6. One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis. 7. Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.) 8. Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed. Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+ 9. UGT1A1 genotype tested. Categorized into Wild or single Hetero. Exclusion Criteria: 1. Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field. 2. Untreated brain metastases or spinal cord compression or primary brain tumors. 3. History of CNS disease.[except for asymptomatic Lacunar stroke] 4. Requiring chronic systemic corticosteroid treatment. 5. Current or recent ongoing treatment with anticoagulants. 6. Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication. 7. Treatment with any investigational drug within 4 weeks. 8. Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea, >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases. 9. Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure.[except for implantation of central venous catheter and port system.] 10. Lack of physical integrity of the upper gastrointestinal tract. 11. Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males. 12. Hepatitis B or hepatitis C. Evidence of HIV infection. 13. Previous Chemotherapy for other organs. 14. Other active co-existing malignancies. 15. History / Presence of thrombosis within 1 year requiring medication. 16. History / Presence of paralytic ileus, obstruction or gastrointestinal perforation. 17. Malignant coelomic fluid required drainage. 18. History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications. 19. History of fluoropyrimidine severe side effects caused by DPD defect. 20. Interstitial pneumonitis or pulmonary fibrosis. 21. Evidence or requiring systemic treatment for Infectious disease. 22. Patient who is judged by the investigator to be inappropriate for study participation for any reason.

Additional Information

Official title A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer
Principal investigator Takeshi Kato, M.D., Ph.D
Description This is a single-arm, multicentre phase II study evaluating the efficacy and safety of Bevacizumab (BV) in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al. ASCO2013) as first-line treatment for Japanese metastatic colorectal cancer patients. This study is composed two steps because of collecting safety issue in Japanese patient. As First step (Step 1), It assess on the initial safety information in ten Japanese patients of the end of 2nd cycle. it is evaluated by DMC. In parallel with the confirmation of the initial safety issue, register up to 65 cases in total and Step 1 patient, to evaluate the efficacy and safety (Step2).
Trial information was received from ClinicalTrials.gov and was last updated in August 2015.
Information provided to ClinicalTrials.gov by EPS Corporation.